By Pushkala Aripaka
LONDON, Feb 11 (Reuters) - AstraZeneca expects to
produce more than 100 million doses of its COVID-19 vaccine -
developed with Oxford University - this month, ramping up to
more than 200 million a month by April, Chief Executive Pascal
Soriot said on Thursday.
Mene Pangalos, head of BioPharmaceuticals R&D at the British
drugmaker earlier said the company expects much-anticipated data
for the late-stage U.S. trial of its vaccine before the end of
March.
A read-out on data is "only weeks away", he said on a media
call after release of the company's 2020 results.
(Reporting by Pushkala Aripaka and Ludwig Burger
Writing by Josephine Mason
Editing by David Goodman
)